With the U.S. declaration of a national health emergency the TPOXX drug could soon be more widely available under an EUA.
The company itself does not have its own production facilities but instead relies on third-party production sources.
This means the company’s CAP X is very low and they can scale up production if required.
If the monkey pox outbreak warrants the company can produce up to 500,000 courses a year with the current capacity.
In pill form, the drug is taken over a period of two weeks and this is a course.
The price for each course for international customers Is $900-$1000 per course.
In the US it is $300-$400.
Pricing differs depending on the size of the order.
Should the company deliver 500,000 courses in a single year it’s revenue from Tecovirimat would be $500 million in that year.
Revenue (TTM) was 139.4 million as per last reporting, so the growth potential for the company and its share price is significant.
Especially if ( as is now predicted by many health professionals) Monkeypox becomes endemic globally.
Link to SIGA Technologies earnings report.
Leave a Reply